Cargando…

A cosmeceutical formulation based on boswellic acids for the treatment of erythematous eczema and psoriasis

BACKGROUND: Boswellic acids (BAs) show anti-inflammatory properties in a variety of inflammatory diseases, including rheumatoid arthritis, osteoarthritis, and asthma. A topical administration route is currently used to deliver active compounds in psoriatic and eczematous patients. In this double-bli...

Descripción completa

Detalles Bibliográficos
Autores principales: Togni, Stefano, Maramaldi, Giada, Di Pierro, Francesco, Biondi, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4235203/
https://www.ncbi.nlm.nih.gov/pubmed/25419153
http://dx.doi.org/10.2147/CCID.S69240
_version_ 1782344986643136512
author Togni, Stefano
Maramaldi, Giada
Di Pierro, Francesco
Biondi, Massimo
author_facet Togni, Stefano
Maramaldi, Giada
Di Pierro, Francesco
Biondi, Massimo
author_sort Togni, Stefano
collection PubMed
description BACKGROUND: Boswellic acids (BAs) show anti-inflammatory properties in a variety of inflammatory diseases, including rheumatoid arthritis, osteoarthritis, and asthma. A topical administration route is currently used to deliver active compounds in psoriatic and eczematous patients. In this double-blind study we compare a novel BA formulation (containing Bosexil(®), INCI [International Nomenclature of Cosmetic Ingredients]: lecithin, Boswellia serrata resin extract) with a placebo formulation. A third arm of the trial received a formulation of Vaccinium myrtillus seed oil, previously demonstrated as an effective local treatment for psoriatic lesions. METHODS: Patients with psoriasis or erythematous eczema were randomly assigned, in a 1:1:1 ratio, to Bosexil(®), V. myrtillus seed oil, or placebo. In order to evaluate the effects of treatment, the changes of scales and erythema from diagnosis to the end of treatment were scored in psoriatic patients, while changes in itch and erythema were analyzed for erythematous eczema patients. Psoriasis Area Severity Index and Eczema Area and Severity Index scores were also calculated. RESULTS: In patients with psoriasis, scales and erythema improved both with Bosexil(®) and the V. myrtillus seed oil treatment in comparison with placebo. In particular, the treatment with Bosexil(®) formulation improved scales (70% of cases) and erythema (50% of cases) without any case of worsening. In patients with eczema, the administration of placebo did not result in any improvement in 90% of cases, and in the remaining 10% worsened both itch and erythema. Bosexil(®) formulation improved both itch (60% of cases) and erythema (60% of cases) without any case of worsening. V. myrtillus seed oil improved itch and erythema in 66.7% and 77.8% of patients, respectively. CONCLUSION: A topical formulation of Bosexil(®) may be promising for the treatment of psoriasis and erythematous eczema. Long-term studies are recommended to evaluate the adherence to this topical treatment and its clinical benefits in real life.
format Online
Article
Text
id pubmed-4235203
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-42352032014-11-21 A cosmeceutical formulation based on boswellic acids for the treatment of erythematous eczema and psoriasis Togni, Stefano Maramaldi, Giada Di Pierro, Francesco Biondi, Massimo Clin Cosmet Investig Dermatol Original Research BACKGROUND: Boswellic acids (BAs) show anti-inflammatory properties in a variety of inflammatory diseases, including rheumatoid arthritis, osteoarthritis, and asthma. A topical administration route is currently used to deliver active compounds in psoriatic and eczematous patients. In this double-blind study we compare a novel BA formulation (containing Bosexil(®), INCI [International Nomenclature of Cosmetic Ingredients]: lecithin, Boswellia serrata resin extract) with a placebo formulation. A third arm of the trial received a formulation of Vaccinium myrtillus seed oil, previously demonstrated as an effective local treatment for psoriatic lesions. METHODS: Patients with psoriasis or erythematous eczema were randomly assigned, in a 1:1:1 ratio, to Bosexil(®), V. myrtillus seed oil, or placebo. In order to evaluate the effects of treatment, the changes of scales and erythema from diagnosis to the end of treatment were scored in psoriatic patients, while changes in itch and erythema were analyzed for erythematous eczema patients. Psoriasis Area Severity Index and Eczema Area and Severity Index scores were also calculated. RESULTS: In patients with psoriasis, scales and erythema improved both with Bosexil(®) and the V. myrtillus seed oil treatment in comparison with placebo. In particular, the treatment with Bosexil(®) formulation improved scales (70% of cases) and erythema (50% of cases) without any case of worsening. In patients with eczema, the administration of placebo did not result in any improvement in 90% of cases, and in the remaining 10% worsened both itch and erythema. Bosexil(®) formulation improved both itch (60% of cases) and erythema (60% of cases) without any case of worsening. V. myrtillus seed oil improved itch and erythema in 66.7% and 77.8% of patients, respectively. CONCLUSION: A topical formulation of Bosexil(®) may be promising for the treatment of psoriasis and erythematous eczema. Long-term studies are recommended to evaluate the adherence to this topical treatment and its clinical benefits in real life. Dove Medical Press 2014-11-11 /pmc/articles/PMC4235203/ /pubmed/25419153 http://dx.doi.org/10.2147/CCID.S69240 Text en © 2014 Togni et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Togni, Stefano
Maramaldi, Giada
Di Pierro, Francesco
Biondi, Massimo
A cosmeceutical formulation based on boswellic acids for the treatment of erythematous eczema and psoriasis
title A cosmeceutical formulation based on boswellic acids for the treatment of erythematous eczema and psoriasis
title_full A cosmeceutical formulation based on boswellic acids for the treatment of erythematous eczema and psoriasis
title_fullStr A cosmeceutical formulation based on boswellic acids for the treatment of erythematous eczema and psoriasis
title_full_unstemmed A cosmeceutical formulation based on boswellic acids for the treatment of erythematous eczema and psoriasis
title_short A cosmeceutical formulation based on boswellic acids for the treatment of erythematous eczema and psoriasis
title_sort cosmeceutical formulation based on boswellic acids for the treatment of erythematous eczema and psoriasis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4235203/
https://www.ncbi.nlm.nih.gov/pubmed/25419153
http://dx.doi.org/10.2147/CCID.S69240
work_keys_str_mv AT tognistefano acosmeceuticalformulationbasedonboswellicacidsforthetreatmentoferythematouseczemaandpsoriasis
AT maramaldigiada acosmeceuticalformulationbasedonboswellicacidsforthetreatmentoferythematouseczemaandpsoriasis
AT dipierrofrancesco acosmeceuticalformulationbasedonboswellicacidsforthetreatmentoferythematouseczemaandpsoriasis
AT biondimassimo acosmeceuticalformulationbasedonboswellicacidsforthetreatmentoferythematouseczemaandpsoriasis
AT tognistefano cosmeceuticalformulationbasedonboswellicacidsforthetreatmentoferythematouseczemaandpsoriasis
AT maramaldigiada cosmeceuticalformulationbasedonboswellicacidsforthetreatmentoferythematouseczemaandpsoriasis
AT dipierrofrancesco cosmeceuticalformulationbasedonboswellicacidsforthetreatmentoferythematouseczemaandpsoriasis
AT biondimassimo cosmeceuticalformulationbasedonboswellicacidsforthetreatmentoferythematouseczemaandpsoriasis